March 30, 2011
Seikagaku Corporation
(Securities Code: 4548)

# Seikagaku Announces Withdrawal of PMA for Additional Indication of SUPARTZ® in the U.S.

Tokyo, Japan, DATE March 30, 2011 – Seikagaku Corporation (head office: Chiyoda-ku, Tokyo) today announced that it has submitted a notice of withdrawal of the premarket approval application (PMA) for an additional indication for SUPARTZ®, a hyaluronic acid based agent to treat joint pain.

SUPARTZ® is currently marketed in the U.S. as treatment for knee osteoarthritis. Seikagaku conducted a pivotal clinical trial for an additional indication for treatment of shoulder osteoarthritis (development code: SI-602) and submitted the PMA in September 2009. Following subsequent discussions with the U.S. Food and Drug Administration (FDA), Seikagaku has decided that additional clinical studies would be needed to fully develop SUPARTZ® for use in the shoulder indication and, as a result, Seikagaku made the decision to withdraw the application.

The market for knee osteoarthritis treatment in the U.S. is expanding, and Seikagaku will continue to strengthen sales activities of SUPARTZ®. SUPARTZ® is distributed in the U.S. by Smith & Nephew, Inc.

XXXXXXX